Resistance to enfuvirtide, the first HIV fusion inhibitor

The Journal of Antimicrobial Chemotherapy
Michael Greenberg, Nick Cammack

Abstract

Fusion inhibitors are a new class of antiretroviral drugs (ARVs) for the treatment of human immunodeficiency virus infection. Enfuvirtide is the first in this class to reach market approval. Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral capsid entry into the host cell. Enfuvirtide has a unique mechanism of action and high viral target specificity, and in clinical trials has been shown to exhibit both high efficacy and low toxicity. Enfuvirtide is a peptide mimetic of an essential region within viral envelope glycoprotein gp41 that functions by blocking gp41 structural rearrangements at a transitional pre-fusion conformation. Although different clinical isolates show variation in susceptibility to enfuvirtide, primary resistance has not been observed, and thus enfuvirtide-naive isolates remain clinically sensitive. Acquired resistance centres round a 10 amino acid motif between residues 36 and 45 in gp41 that forms part of the binding site of enfuvirtide. The 10 amino acid motif is critical for viral fusion, and enfuvirtide-resistant mutants show poor replicative capacity compared with wild type. Reversion to a wild-t...Continue Reading

Citations

Oct 8, 2013·Bioorganic & Medicinal Chemistry Letters·Junpeng Xiao, Thomas J Tolbert
Nov 24, 2012·Nutrition Research Reviews·Cathríona Rosemary Loonam, Anne Mullen
Mar 17, 2010·Biochemistry·Brian E McGillickRobert C Rizzo
Feb 12, 2009·Journal of the American Chemical Society·Edina BaloghMiriam Gochin
Apr 28, 2006·Nature Reviews. Immunology·Michael M LedermanOliver Hartley
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·Guofeng ChengFrancis V Chisari
Oct 15, 2008·Proceedings of the National Academy of Sciences of the United States of America·Yuxian HeQiuyun Dai
Jul 21, 2009·The Journal of Biological Chemistry·Dirk EgginkRogier W Sanders
Jun 9, 2012·The Journal of Biological Chemistry·Xue YaoSheng Cui
Nov 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pamela Bean
Jul 2, 2005·AIDS Research and Human Retroviruses·Eva PovedaVincent Soriano
Apr 25, 2007·AIDS Research and Human Retroviruses·Francesca RazzoliniMaurizio Zazzi
Dec 28, 2007·AIDS Research and Human Retroviruses·Susan H EshlemanNatalia Marlowe
Sep 1, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Luciana Santos PessoaAmilcar Tanuri
Dec 24, 2010·Science Translational Medicine·Wolf-Georg ForssmannReinhold E Schmidt
Jun 16, 2010·Antimicrobial Agents and Chemotherapy·Agnès DepatureauxJean-Christophe Plantier
Nov 14, 2012·Antimicrobial Agents and Chemotherapy·Frances BrauerLisa Egerer
Oct 27, 2007·Retrovirology·Chris Baldwin, Ben Berkhout

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.